AccueilREPCF • OTCMKTS
add
RepliCel Life Sciences Inc
Dernière clôture
0,010 $
Capitalisation boursière
551,83 k CAD
Volume moyen
2,94 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
CVE
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
(CAD) | sept. 2024info | Variation Y/Y |
---|---|---|
Chiffre d'affaires | 88,43 k | 0,00 % |
Charges d'exploitation | 168,09 k | -59,39 % |
Résultat net | -216,22 k | 73,59 % |
Marge bénéficiaire nette | -244,50 | 73,59 % |
Bénéfice par action | — | — |
EBITDA | -79,52 k | 75,57 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
(CAD) | sept. 2024info | Variation Y/Y |
---|---|---|
Trésorerie/Invest. court terme | 10,46 k | -67,78 % |
Total des actifs | 150,97 k | -54,45 % |
Total du passif | 5,34 M | -23,30 % |
Total des capitaux propres | -5,19 M | — |
Actions en circulation | 65,00 M | — |
Ratio cours/valeur comptable | -0,12 | — |
Rentabilité des actifs | -123,05 % | — |
Retour sur capitaux | 5,23 % | — |
Flux de trésorerie
Variation nette en trésorerie
(CAD) | sept. 2024info | Variation Y/Y |
---|---|---|
Résultat net | -216,22 k | 73,59 % |
Trésorerie (opérations) | -53,11 k | 73,48 % |
Trésorerie (invest.) | 0,00 | — |
Trésorerie (financement) | 44,63 k | 4 463 500,00 % |
Variation nette en trésorerie | -8,48 k | 95,77 % |
Flux de trésorerie dispo. | -86,26 k | 63,60 % |
À propos
RepliCel Life Sciences is a Canadian regenerative medicine company based in Vancouver, British Columbia. The company focuses on development of cell therapies using a patient's own cells. The company has treatment development activities targeting chronic tendon injuries which have failed to heal properly, and hair restoration. The company's expertise lies in isolation and exploitation of different cell populations found in the human hair follicle.
The company's business model is focused on establishing proof-of-concept for treatments leading to acquisition by a larger company. An alternative business model has been reported which does not involve acquisition but rather partnership where technologies and methods are licensed to a partner which will commercialize them. Wikipedia
Date de fondation
1967
Siège social
Site Web
Employés
1